Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 10/20 | 0.56 |
| ▸ | HTR2A | P28223 | 5/20 | 0.50 |
| ▸ | HRH1 | P35367 | 2/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.42 |
| ▸ | HTR1D | P28221 | 2/20 | 0.41 |
| ▸ | HTR1B | P28222 | 2/20 | 0.41 |
| ▸ | HTR7 | P34969 | 2/20 | 0.41 |
| ▸ | HTR6 | P50406 | 2/20 | 0.41 |
| ▸ | MPO | P05164 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5185563 | 0.84 | MAOA (0.50) | TAAR1HTR2AHRH1MPO | |
| SCHEMBL8698489 | 0.84 | TAAR1 (0.35) | TAAR1HTR1A | |
| SCHEMBL224549 | 0.81 | TAAR1 (0.70) | TAAR1HTR2AHRH1CYP2A6SMN1; SMN2 | |
| SCHEMBL5184014 | 0.79 | — | — | |
| SCHEMBL2907330 | 0.75 | TAAR1 (0.60) | TAAR1HTR2AHRH1CYP2A6SMN1; SMN2 | |
| SCHEMBL810350 | 0.75 | TDP1 (0.44) | TAAR1SMN1; SMN2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL186669 | 0.75 | GABRA1 (0.37) | ADRA2CHTR1A | |
| SCHEMBL6829700 | 0.75 | ALDH1A1 (0.34) | TAAR1 | |
| SCHEMBL28597876 | 0.75 | TAAR1 (0.56) | TAAR1HTR2AHRH1CYP2A6SMN1; SMN2 | |
| SCHEMBL3051426 | 0.74 | TAAR1 (0.61) | TAAR1HTR2AHRH1CYP2A6SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3011961-B1 | 4F-BENZOYL-TN14003 FOR THE MOBILISATION OF HEMATOPOIETIC PROGENITOR CELLS IN VIEW OF TRANSPLANTATION | BIOKINE THERAPEUTICS LTD (IL) | 2020-11-11 | — | — | EP | disclosed |
| EP-2841084-B1 | CXCR4 ANTAGONIST PEPTIDE FOR USE IN THE TREATMENT OF LARGE CELL LUNG CANCER | BIOKINE THERAPEUTICS LTD (IL) | 2018-05-30 | — | — | EP | disclosed |
| US-9439942-B2 | Peptides and use thereof in the treatment of large cell lung cancer | BIOKINE THERAPEUTICS LTD. (IL) | 2016-09-13 | — | — | US | disclosed |
| EP-3011961-A1 | 4F-benzoyl-TN14003 for the mobilisation of hematopoietic progenitor cells in view of transplantation | Biokine Therapeutics LTD. (IL) | 2016-04-27 | — | — | EP | disclosed |
| EP-2942059-A1 | 4F-BENZOYL-TN14003 FOR USE IN THE TREATMENT OF MULTIPLE MYELOMA | Biokine Therapeutics LTD. (IL) | 2015-11-11 | — | — | EP | disclosed |
| US-20150125549-A1 | PEPTIDES AND USE THEREOF IN THE TREATMENT OF LARGE CELL LUNG CANCER | BIOKINE THERAPEUTICS LTD. (IL) | 2015-05-07 | — | — | US | disclosed |
| EP-2841084-A1 | PEPTIDES AND USE THEREOF IN THE TREATMENT OF LARGE CELL LUNG CANCER | Biokine Therapeutics Ltd. (IL) | 2015-03-04 | — | — | EP | disclosed |
| EP-2426139-B1 | CXCR4 antagonist and use thereof | BIOKINE THERAPEUTICS LTD (IL) | 2014-10-01 | — | — | EP | disclosed |
| EP-2759302-A2 | 4F-benzoyl-TN14003 combined with rituximab for use in the treatment of a tumour | Biokine Therapeutics LTD. (IL) | 2014-07-30 | — | — | EP | disclosed |
| EP-2442822-B1 | PEPTIDE THERAPY FOR INCREASING PLATELET LEVELS | BIOKINE THERAPEUTICS LTD (IL) | 2014-03-05 | — | — | EP | disclosed |
| WO-2008075369-A2 | T-140 PEPTIDE ANALOGS HAVING CXCR4 SUPER-AGONIST ACTIVITY FOR BONE MARROW RECOVERY | BIOKINE THERAPEUTICS LTD. (IL) | 2008-06-26 | — | — | WO | disclosed |
| EP-1898943-A2 | CXCR4 ANTAGONISTS FOR WOUND HEALING AND RE-EPITHELIALIZATION | Hadasit Medical Research Services & Development Ltd. (IL) | 2008-03-19 | — | — | EP | disclosed |
| EP-1273608-B1 | FLAME-RETARDANT EPOXY RESIN COMPOSITION, MOLDED OBJECT THEREOF, AND ELECTRONIC PART | OTSUKA KAGAKU KK (JP) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006126188-A2 | CXCR4 ANTAGONISTS FOR WOUND HEALING AND RE-EPITHELIALIZATION | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2006-11-30 | — | — | WO | disclosed |
| EP-1541585-A1 | CXCR4 ANTAGONIST AND USE THEREOF | Fujii, Nobutaka (JP) | 2005-06-15 | — | — | EP | disclosed |
| EP-1483263-A1 | THIAZOLYL UREA COMPOUNDS FOR THE TREATMENT OF CANCER | Amgen Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| US-6797750-B2 | Flame-retardant epoxy resin composition, molded article thereof, and electronic part | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 2004-09-28 | — | — | US | disclosed |
| WO-2003070727-A1 | THIAZOLYL UREA COMPOUNDS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2003-08-28 | — | — | WO | disclosed |
| US-20030114606-A1 | A phosphazene compound or polyphosphazenes; fireproofing | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 2003-06-19 | — | — | US | disclosed |
| EP-1273608-A1 | FLAME-RETARDANT EPOXY RESIN COMPOSITION, MOLDED OBJECT THEREOF, AND ELECTRONIC PART | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 2003-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150125549-A1 | PEPTIDES AND USE THEREOF IN THE TREATMENT OF LARGE CELL LUNG CANCER | NGLY1, VIP, TAP1 | TAAR1 3851/4885HTR2A 4805/4885HRH1 3525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.